Key Figures (IFRS)

morphosys group (in € million, if not stated otherwise)

  12/31/12   12/31/11   12/31/10   12/31/09   12/31/08   12/31/07   12/31/06   12/31/05   12/31/04  
Results1)
Revenues 51.9 82.1 87.0 81.0 71.6 62.0 53.0 33.5 22.0
Cost of Goods Sold 0.0 0.0 7.3 6.7 7.1 7.9 8.0 2.5 0.97)
R&D Expenses 37.7 55.9 46.9 39.0 27.6 22.2 17.5 14.0 11.47)
S, G&A Expenses 12.1 14.9 23.2 23.9 20.5 24.8 21.4 10.8 7.57)
Personnel Expenses
(Excluding Stock-based Compensation)
24.1 27.7 29.6 26.1 21.5 18.8 18.1 10.8 9,1
Capital Expenditure 1.8 2.9 13.8 3.8 3.8 12.0 4.0 0.7 1,7
Depreciation and Amortization
of Tangible Assets
1.7 1.7 2.1 1.6 1.5 1.5 1.5 0.9 0,7
Depreciation and Amortization
of Intangible Assets
3.5 3.8 4.0 3.8 4.8 3.7 3.4 2.7 2,0
EBITDA 7.9 15.5 19.2 18.1 21.9 13.3 10.3 8.6 3,2
EBIT 2.5 9.8 13.1 12.8 16.5 8.3 5.4 5.3 0,5
Net Profit/(Loss) 1.9 8.2 9.2 9.0 13.2 11.5 6.0 4.7 0,3
Net Profit/(Loss) from
Discontinued Operations
- 0.4 0.0
Balance Sheet2)
Total Assets 224.3 228.44) 209.84) 206.1 203.3 184.7 127.8 80.1 55.8
Cash, Cash Equivalents and
Available-for-sale Financial Assets
135.75) 134.4 108.4 135.1 137.9 106.9 66.0 53.6 37.2
Intangible Assets 35.0 66.0 69.2 17.4 19.7 22.3 14.8 12.4 12.8
Total Liabilities 22.3 31.34) 23.94) 32.2 41.3 39.2 27.8 16.1 16.4
Stockholders' Equity 202.2 197.1 185.9 173.9 162.0 145.5 100.1 64.0 39.4
Equity Ratio (in %) 90% 86% 89% 84% 80% 79% 78% 80% 71%
MorphoSys Share
Number of Shares Issued 23,358,228 23,112,167 22,890,252 22,660,557 22,478,787 22,160,259 20,145,966 18,077,589 16,316,556
Earnings/(Loss) per Share, Diluted (in €) 0.086) 0.366) 0.40 0.40 0.59 0.53 0.31 0.28 0.02
Dividend (in €) - - - - - - - - -
Share Price (in €) 29.30 17.53 18.53 17.04 18.75 16.10 18.12 13.77 12.70
Personnel Data3)
Total Group Employees (Number) 421 446 464 404 334 295 279 172 132
Germany (Number) 328 352 370 301 236 192 183 145 132
Other Countries (Number) 93 94 94 103 98 103 96 27 -

1) Due to the Agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the segment AbD Serotec, for the years 2012 and 2011, revenue, income and expenses in connection with the transaction are shown in the line item ‘Profit/(Loss) from Discontinued Operations’. All other line items consist of amounts from continuing operations.

2) Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the segment AbD Serotec, for the year 2012, the line item ‘Total Assets’ includes current and non-current assets in connection with the transaction in the amount of € 40.9 million. The line item ‘Total Liabilities’ includes for the year 2012 current and non-current liabilities in connection with the transaction in the amount of € 3.7 million.

3) The total amount 2012 includes 135 employees from discontinued operations of AbD Serotec.

4) In 2011, a deferred tax asset in the amount of € 2.3 million has been offset with a deferred tax liability for better transparency. Both deferred tax asset and deferred tax liability relate to income taxes levied by the same tax authority on the same taxable entity. To provide comparative information, prior year’s deferred tax asset and deferred tax liability (€ 2.8 million) – and thus total assets as well as total liabilities and stockholders’ equity – have been adjusted accordingly.

5) Including an interest-bearing assignable loan in the amount of € 10.0 million and including cash reserves of the discontinued AbD Serotec segment in the amount of € 5.3 million.

6) Consolidated net profit per share (diluted) including discontinued operations from the AbD Serotec segment.

7) Excluding stock-based compensation.